NCT01783587View on ClinicalTrials.gov

Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

November 20, 2017

Study Completion Date

June 1, 2018

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Afatinib

Taken orally once per day

DRUG

Docetaxel

15 mg/m2, given intravenously once per week

RADIATION

Radiation Therapy

Daily, Monday-Friday, for six to seven weeks

Trial Locations (3)

10029

Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai, New York

02115

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Comprehensive Cancer Network

NETWORK

lead

Dana-Farber Cancer Institute

OTHER

NCT01783587 - Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer | Biotech Hunter | Biotech Hunter